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Abstract
Background: The serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination
campaigns in December 2010 in Burkina Faso, Mali and Niger. In the coming years, vaccination will be extended to other
African countries at risk of epidemics. To document the molecular characteristics of disease-causing meningococcal strains
circulating in the meningitis belt of Africa before vaccine introduction, the World Health Organization Collaborating Centers
on Meningococci in Europe and United States established a common strain collection of 773 isolates from cases of invasive
meningococcal disease collected between 2004 and 2010 from 13 sub-Saharan countries.
Methodology: All isolates were characterized by multilocus sequence typing, and 487 (62%) were also analyzed for genetic
variation in the surface antigens PorA and FetA. Antibiotic susceptibility was tested for part of the collection.
Principal Findings: Only 19 sequence types (STs) belonging to 6 clonal complexes were revealed. ST-5 clonal complex
dominated with 578 (74.8%) isolates. All ST-5 complex isolates were remarkably homogeneous in their PorA (P1.20,9) and
FetA (F3-1) and characterized the serogroup A strains which have been responsible for most epidemics during this time
period. Sixty-eight (8.8%) of the 773 isolates belonged to the ST-11 clonal complex which was mainly represented by
serogroup W135, while an additional 38 (4.9%) W135 isolates belonged to the ST-175 complex. Forty-eight (6.2%) serogroup
X isolates from West Africa belonged to the ST-181 complex, while serogroup X cases in Kenya and Uganda were caused by
an unrelated clone, ST-5403. Serogroup X, ST-181, emerged in Burkina Faso before vaccine introduction.
Conclusions: In the seven years preceding introduction of a new serogroup A conjugate vaccine, serogroup A of the ST-5
clonal complex was identified as the predominant disease-causing strain.
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Introduction
The meningitis belt of Africa was first described by Lapeysonnie
in 1963 [1] and was further defined by Molesworth and co-
workers in 2002 [2]. It now encompasses parts or the whole of 25
countries south of the Sahara, stretching from Ethiopia in the east
to Senegal in the west. Every year during the dry season the region
is affected by outbreaks of meningococcal meningitis and large
epidemics emerge unpredictably 8 to 10 years apart. Traditionally,
serogroup A meningococci have been responsible for most of the
endemic disease as well as for the large epidemics, but more
recently serogroup W135 and serogroup X strains have also been
involved [3–13]. Emergence and dissemination of a new strain
may lead to epidemics under certain environmental conditions.
New strains that appeared and were disseminated during the
annual Hajj pilgrimage have been linked to several epidemics [14].
The most severe epidemic of meningococcal meningitis
experienced by Africa was in 1996, with more than 150,000
reported cases and 16,000 deaths [15–17]. It was caused by a
serogroup A clone of Neisseria meningitidis assigned to sequence type
(ST) -5 using multilocus sequence typing [18]. In 2002, Burkina
Faso was the first country to experience a major serogroup W135
epidemic, with 13,000 reported cases, and 1,400 deaths [10]. A
hypervirulent ST-11 clone was responsible for this epidemic [7].
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Preventive vaccination with meningococcal polysaccharide
vaccines was usually not attempted because of their relatively
short protection and low immunogenicity in young children [19].
Thus, the World Health Organization (WHO) recommended
reactive mass vaccination to halt epidemics using either the A/C
or the A/C/W135 polysaccharide vaccines, depending on the
serogroup of the outbreak strains [20].
Starting in 2002, the Meningitis Vaccine Project (MVP), a
public-private partnership between WHO and the Program for
Appropriate Technology in Health (PATH), developed an
effective monovalent serogroup A conjugate meningococcal
vaccine, MenAfriVac, at a price affordable for African countries,
with the aim of eliminating the devastating serogroup A epidemics
occurring in sub-Saharan Africa [21]. The vaccine was introduced
in a country-wide mass vaccination campaign in Burkina Faso in
December 2010, where the vaccine was offered to all individuals
aged 1 to 29 years. Vaccination of the same age group started in
Mali and Niger in 2010 and was completed in 2011 [22].
In 2005 the two WHO Collaborating Centers for Reference
and Research on Meningococci in Marseille, France, and Oslo,
Norway, published an overview on the phenotypic and genotypic
features of meningococcal isolates recovered from meningitis cases
between 1988 and 2003 in 13 countries of the African meningitis
belt [18]. We report here the molecular characteristics of the
strains circulating in these countries from 2004 to 2010, prior to
MenAfriVac introduction. The strain collection established by
these two WHO Collaborating Centers was supplemented with
isolates received by the WHO Collaborating Center for Preven-
tion and Control of Epidemic Meningitis, Centers for Disease
Control and Prevention, Atlanta, GA, and by the Institut Pasteur,
Paris, France, which is a newly nominated WHO Collaborating
Center, following closure of the WHO Center in Marseille in
2010.
Materials and Methods
Bacterial isolates
The strain collection comprised a total of 773 isolates, all
recovered from cerebrospinal fluid samples from patients of
countries of the African meningitis belt and forwarded to the
WHO Collaborating Centres. Strains from patients in other
African countries were excluded, as were isolates from asymp-
tomatic carriers. The sources of the isolates were as follows: 1) a
total of 372 isolates from 2004 to 2009 constituted a large part
(88%) of the collection of invasive isolates from the WHO
Collaborating Centre in Marseille for that period; the isolates were
transferred to the other WHO Collaborating Centres under
contract for scientific purposes; 2) 360 isolates were from the
WHO Collaborating Centre in Oslo. These were assembled either
by physicians working for Médecins Sans Frontières, using Trans-
Isolate media [23] to collect samples in areas where meningitis
outbreaks were occurring; during field evaluations performed by
the WHO Inter-country Support Team, Ouagadougou; or directly
by the co-authors; 3) the remaining isolates were sent to the WHO
Collaborating Centre by co-authors. Bacterial identification was
determined by Gram staining, the oxidase reaction, and standard
biochemical tests. The strains were stored at 280uC in brain heart
broth with 15% sterile glycerol or in Greaves solution [24].
Serogrouping
N. meningitidis strains were serogrouped by slide agglutination
with sera manufactured by the Institut de Médecine Tropicale du
Service de Santé des Armées, Marseilles, France, or commercial
antisera (Remel, GA, USA).
Antimicrobial sensitivity testing
Antimicrobial susceptibility testing was performed by determi-
nation of the minimal inhibitory concentrations (MIC) using Etest
(AB Biodisk, Solna, Sweden). Isolates were tested for susceptibility
to penicillin G, amoxicillin, ceftriaxone, ciprofloxacin, chloram-
phenicol, rifampin, tetracycline and sulphonamides, and classified
using the breakpoints from the European Committee on
Antimicrobial Susceptibility Testing (http://www.eucast.org/).
Genotypic characterization
DNA from each strain was prepared by suspending bacteria in
Tris-EDTA buffer (10 mM Tris-HCl and 1 mM EDTA), pH 8.0,
heating at 95uC for 10 min, and followed by centrifugation at
16,0006 g for 5 min. The supernatant was used as DNA template
for PCR. After DNA amplification by PCR, sequence of fragments
from the seven housekeeping genes, abcZ (putative ABC
transporter), adk (adenylate kinase), aroE (shikimate dehydroge-
nase), fumC (fumarase), gdh (glucose-6-phosphate dehydrogenase),
pdhC (pyruvate dehydrogenase subunit), and pgm (phosphogluco-
mutase), were analysed on an AB Prism 373, AB Prism 377 or AB
3130XL DNA sequencer (Applied Biosystems, Foster City, CA),
according to the method on the MLST website (http://pubmlst.
org/neisseria/). The DNA sequences were compared with the
existing alleles on the MLST website using sequence query or the
meningococcal genome informatics platform (MGIP) for determi-
nation of the allele numbers, STs, and clonal complexes of the
isolates [25].
Variation in the porA and fetA genes, coding for the outer
membrane proteins PorA and FetA, respectively, was determined
by DNA sequencing, as described previously [26,27]. New MLST
alleles and STs were submitted to the MLST database (http://
pubmlst.org/neisseria/), together with the strain serogroup and
porA and fetA sequences.
PCR analysis of the genes coding for the polysaccharide capsule
was performed for genogroup determination of non-serogroupable
isolates as described [28].
Data analyses
All the data were entered into an Excel database (Microsoft
Corporation, Redmond, WA) and analysed using R version 2.10.0
[29].
Results
Origin of isolates
The isolates analysed by MLST originated from Benin (n = 12),
Burkina Faso (n = 285), Cameroon (n = 24), Central African
Republic (CAR) (n = 5), Chad (n = 53), Ghana (n = 6), Kenya
(n = 3), Mali (n = 132), Niger (n = 124), Nigeria (n = 57), Sudan
(n = 22), Togo (n = 29) and Uganda (n = 21). The number of
isolates retrieved by country and year varied greatly, ranging from
zero for some countries in some years to 128 from Burkina Faso in
2006 (Table 1). For Burkina Faso, Chad, Mali and Niger,
meningococcal isolates were obtained and characterized for at
least 6 of the 7 years of the period analysed.
Serogroups
Of the 773 isolates, 568 (73.5%) were serogroup A, 105 (13.6%)
serogroup W135, 63 (8.2%) serogroup X, 22 (2.8%) serogroup Y
and 15 (1.9%) were non-groupable (NG). Serogroup W135 was
present in all these 13 countries within the meningitis belt, while
serogroup A was recovered from all countries except Kenya.
Serogroup X was mainly found in Niger, Burkina Faso and
Uganda. Burkina Faso was the only country where all the
N. meningitidis in the Meningitis Belt, 2004–2010
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Table 1. Serogroup and sequence type (ST) of invasive meningococcal isolates from sub-Saharan Africa in 2004–2010.
Year Serogroup Clonal complex ST No. of strains (yearly %) Country source (no. of isolates)
2004 A 5 7 23 (32.4) Benin (1); CARc (4); Ghana (4); Niger (13); Nigeria (1)
A 5 2859 17 (23.9) Burkina Faso (16); Mali (1);
W135 11 11 11 (15.5) Benin (1); Burkina Faso (8); Ghana (2)
W135 23 4375 1 (1.4) Burkina Faso (1);
W135 175 2881 3 (4.2) Benin (1); Chad (1); Nigeria (1)
X 181 181 3 (4.2) Niger (3)
Y 11 11 1 (1.4) Burkina Faso (1)
Y 23 4375 1 (1.4) Burkina Faso (1)
Y 167 767 1 (1.4) Benin (1)
NGa 5 2859 7 (9.9) Burkina Faso (6); Mali (1)
NG 23 4375 2 (2.8) Burkina Faso (2)
NG UAb 192 1 (1.4) Burkina Faso (1)
2005 W135 11 11 6 (35.3) Chad (4); Kenya (2)
W135 175 2881 4 (23.5) Niger (4)
X 181 181 7 (41.2) Niger (7)
2006 A 5 7 36 (16.0) Burkina Faso (1); Mali (1); Niger (25); Nigeria (3); Sudan (6)
A 5 2859 126 (56.0) Burkina Faso (122); Mali (4)
A 5 5788 1 (0.4) Niger (1)
W135 11 11 14 (6.2) Chad (1); Mali (5); Sudan (3); Uganda (5)
W135 11 5779 1 (0.4) Burkina Faso (1)
W135 175 2881 5 (2.2) Benin (3); Niger (2)
X 181 181 23 (10.2) Niger (23)
X 181 5789 1 (0.4) Niger (2)
X UA 5403 9 (4.0) Kenya (1); Uganda (8)
Y 167 2953 1 (0.4) Benin (1)
Y 23 4375 5 (2.2) Burkina Faso (4); Niger (1)
Y 167 767 2 (0.9) Mali (2)
2007 A 5 7 34 (18.6) Chad (4); Mali (3); Niger (12); Nigeria (3); Sudan (12)
A 5 2859 113 (61.7) Burkina Faso (71); Mali (23); Togo (19)
W135 11 11 8 (4.4) Mali (8)
W135 175 2881 8 (4.4) Benin (1); Chad (1); Togo (6)
X 181 181 3 (1.6) Burkina Faso (3)
X UA 5403 6 (3.3) Uganda (6)
Y 23 4375 1 (0.5) Burkina Faso (1)
Y 167 767 4 (2.2) Mali (4)
Y 167 2880 1 (0.5) Burkina Faso (1)
Y 167 8620 1 (0.5) Mali (1)
Y UA 192 1 (0.5) Mali (1)
NG 5 2859 2 (1.1) Burkina Faso (1); Mali (1)
NG UA 192 1 (0.5) Burkina Faso (1)
2008 A 5 7 18 (16.8) Mali (3); Niger (7); Nigeria (7); Sudan (1)
A 5 2859 62 (57.9) Burkina Faso (24); Mali (36); Niger (2)
A 5 6968 1 (0.9) Burkina Faso (1)
W135 11 11 5 (4.7) Cameroon (1); CAR (1); Chad (3)
W135 175 2881 13 (12.1) Benin (1); Burkina Faso (1); Cameroon (9); Togo (2)
X 181 181 3 (2.8) Benin (1); Togo (2)
Y 23 4375 1 (0.9) Burkina Faso (1)
Y 167 767 2 (1.9) Benin (1); Mali (1)
NG 5 2859 1 (0.9) Mali (1)
N. meningitidis in the Meningitis Belt, 2004–2010
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serogroups were isolated. No serogroup B or C isolate was
recovered from any of the countries.
Genogrouping was performed on the 11 of the 15 NG isolates
that were still available. The genes for serogroup A and serogroup
Y capsule were detected in 5 and 2 isolates, respectively, but no
PCR product was obtained with any of the primer sets for the
remaining 4 isolates.
Antibiotic susceptibility
Antimicrobial susceptibility testing was performed for a
selection of isolates (Table 2). All isolates tested were susceptible
to amoxicillin, ceftriaxone, ciprofloxacin, chloramphenicol and
rifampin. Of the 336 isolates tested against sulphonamide, all but 9
were resistant; the exceptions were 8 serogroup X isolates from
Burkina Faso and a serogroup W135 isolate from Kenya. Among
the isolates tested against tetracycline, all serogroup A strains were
resistant while all the serogroup W135 and X isolates were
susceptible. Reduced susceptibility to penicillin was seen for 9% of
the isolates, but there was no association with the serogroup of the
strains.
Molecular characterisation
The ST-5 clonal complex dominated the strain collection with
578 isolates (74.8%), followed by 68 (8.8%) isolates of ST-11
complex, 48 (6.2%) isolates of ST-181 complex, 38 (4.9%) isolates
of ST-175 complex, 12 (1.6%) isolates of ST-23 complex and 11
(1.4%) isolates of ST-167 complex (Table 3). The remaining 18
isolates belong to a ST that cannot be assigned to any ST complex;
ST-192 (3 isolates) and ST-5403 (15 isolates).
The dominating ST-5 complex was composed of 368 (63.7%)
ST-2859 isolates, 207 (35.8%) ST-7 isolates, as well as one isolate
(0.2%) of each of the STs 6968, 5788 and 8639. The isolates of the
ST-5 complex were either serogroup A (568 isolates) or NG (10
isolates) and a total of 344 ST-5 complex isolates that were further
subtyped had identical PorA (P1.20,9) and FetA (F3-1). All
serogroup A isolates belonged to the ST-5 complex.
The ST-11 clonal complex included 66 (97%) ST-11 isolates
and two SLVs of ST-11, ST-5779 and ST-8637, both with one
isolate each. The ST-11 complex was mainly composed of
serogroup W135 isolates (97%). All 53 W135 ST-11 complex
isolates for which PorA was sequenced were P1.5,2. FetA variant
Table 2. Antibiotic susceptibility of invasive meningococcal isolates from sub-Saharan Africa in 2004–2010.
% of isolates
Antibiotic No. of isolates tested MIC range (mg/ml) Susceptible Intermediate Resistant
Penicillin G 526 0.012–0.64 91 7 2
Amoxicillin 189 0.012–0.19 100 0 0
Ceftriaxone 364 0.001–0.004 100 0 0
Ciprofloxacin 336 0.003–0.008 100 0 0
Chloramphenicol 526 0.38–2 100 0 0
Rifampin 508 0.002–0.25 100 0 0
Tetracycline 169 0.125–8 20 0 80
Sulphonamide 336 0.025–$1024 2 0 98
doi:10.1371/journal.pone.0046019.t002
Table 1. Cont.
Year Serogroup Clonal complex ST No. of strains (yearly %) Country source (no. of isolates)
NG 11 11 1 (0.9) Chad (1)
2009 A 5 7 60 (65.2) Cameroon (1); Chad (1); Niger (21); Nigeria (37)
A 5 2859 16 (17.4) Burkina Faso (6); Mali (9); Niger (1)
W135 11 11 12 (13.0) Cameroon (6); Chad (3); Mali (1); Nigeria (2)
W135 175 2881 4 (4.3) Cameroon (4)
2010 A 5 7 36 (46.2) Cameroon (1); Chad (29); Mali (3); Nigeria (1); Uganda (2)
A 5 2859 24 (30.8) Burkina Faso (2); Mali (22)
A 5 8639 1 (1.3) Burkina Faso (1)
W135 11 11 8 810.3) Cameroon (2); Chad (5); Nigeria (1)
W135 11 8637 1 (1.3) Nigeria (1)
W135 175 8638 1 (1.3) Burkina Faso (1)
X 181 181 7 (9.0) Burkina Faso (7)
aNG, Non-groupable as determined by slide agglutination method.
bUA, Unassigned to any clonal complex.
cCAR, Central African Republic.
doi:10.1371/journal.pone.0046019.t001
N. meningitidis in the Meningitis Belt, 2004–2010
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F1-1 dominated within the ST-11 complex with 92.7% of
sequenced isolates.
The other clonal complex associated with serogroup W135 was
the ST-175 complex, with 37 isolates (97.4%) of ST-2881 and one
isolate of ST-8638, a SLV of ST-2881 identified in Burkina Faso
in 2010. The dominant PorA-FetA combination among the 20
sequenced ST-175 complex isolates was P1.5-1,2-36/F5-1 (85%).
The ST-181 clonal complex consisted of ST-181 (95.8%) and
ST-5789 (4.2%), a SLV of ST-181 at the adk locus, first
encountered in Niger in 2006. All these isolates were serogroup
X. Of the 27 ST-181 complex isolates analyzed for PorA and
FetA, all were P1.5-1,10-1, while FetA varied with 74% F1–31,
22% F4–23, and 4% F5–69. All 48 ST-181 complex isolates
originated from West Africa: Niger (n = 35), Burkina Faso (n = 10),
Benin (n = 1) and Togo (n = 2).
Serogroup X causing disease in East Africa (Kenya and
Uganda) belonged to ST-5403, a clone unrelated to the ST-181
complex and not yet assigned to a clonal complex. Of the 15 ST-
5403 isolates that were sequenced for porA and fetA genes, 14 were
P1.19,26/F3–27; one was P1.19,26-4/F3–27.
The serogroup Y isolates were mostly represented by the ST-23
and ST-167 clonal complexes. The ST-23 complex comprised 11
isolates of ST-4375 originating from Burkina Faso (n = 10) and
Niger (n = 1), as well as one ST-2954 isolate from Benin. The ST-
167 complex was represented by nine ST-767 isolates from Benin
(n = 2) and Mali (n = 7), one ST-2880 isolate from Burkina Faso
and one ST-8620 isolates from Mali. Both ST-2880 and ST-8620
are SLVs of ST-767, differing in the aroE and fumC loci,
respectively. Ten of the ST-167 complex isolates were P1.5-
1,10-8/F1–3 and one was P1.5-1,10-8/F3-1. All seven serogroup
Y ST-4375 isolates analyzed were P1.5-1,2-2/F5–8.
Temporal changes within countries
The disease-causing strains varied in individual countries of the
meningitis belt within the reported time interval. For the three
countries with most analyzed isolates, the serogroup distribution
by year is shown in Fig. 1. In Burkina Faso, serogroup A
dominated during the whole period except for 2010, when
serogroups X, A and W135 were represented by 7, 2 and 1 strains,
respectively. In Mali, serogroup A has been responsible for ,80%
of cases in all the years, but in 2006 the proportion of serogroup A
and serogroup W135 isolates was equal. In Niger serogroup A
isolates dominated except for 2005–2006, when serogroup X
prevailed. Unfortunately, we did not obtain any case isolates from
Niger in 2010. However, an increase in isolates of serogroup
W135 and a decline in serogroup X were reported in Niger in
2010 [4].
In Chad, serogroup W135 dominated during the whole period
except for 2007 and 2010, when serogroup A was prevalent; but
the numbers of isolates were small.
Evolution of ST-5 complex
Since the introduction of the ST-5 complex in the meningitis
belt in 1987 [9], variation in housekeeping genes has occurred,
resulting in new STs (Fig. 2). In the period 2004–2010, ST-7,
which had already totally replaced ST-5 in the meningitis belt by
2003 [18], and ST-2859, which emerged in Burkina Faso in 2003,
dominated within the ST-5 complex. In addition, three new STs
emerged during the period 2004–2010: ST-6968, a single locus
variant (SLV) of ST-2859 in the pdhC locus was first identified in
Burkina Faso in 2008; ST-5788 and ST-8639 were first identified
in Niger in 2006 and Mali in 2010, respectively, and are SLVs of
ST-7, in the aroE and pdhC loci, respectively. In contrast, no
variation in the genes coding for the surface exposed outer
membrane proteins PorA and FetA has been detected.
Discussion
This study included 773 isolates recovered from meningococcal
disease cases in 13 countries of the meningitis belt during a 7-year
period. Only 19 distinct STs were revealed. These STs belonged
to 6 clonal complexes, two of which, the ST-5 and the ST-11
complexes, accounted for 83.6% of the isolates.
Limitation of the study
In the period 2004 to 2010 approximately 225,000 meningitis
cases from 12 countries within the African meningitis belt were
reported by the WHO Inter country Support Team – West Africa,
which compiles information from most countries of the sub-
Saharan Africa [30]. This is summarized in Table 4 which showed
a relatively quiet year in 2005 with less than 7,000 reported cases
to the peak year of 2009 with nearly 80,000 reported cases. Of the
reported meningitis cases less than 10% have a clinical specimen
taken and examined microbiologically in the country of origin.
Meningococcal meningitis was laboratory-confirmed for 7803
patients, i.e. about for one third of the patients from whom a
clinical sample was analysed.
Table 3. Distribution of lineages found among 773 N.
meningitidis strains isolated in the African meningitis belt
between 2004 and 2010.
Clonal complex ST Serogroup No. (%) of isolates
ST-5 7 A 207 (26.8%)
2859 A 358 (46.3%)
NGa 10 (1.3%)
5788 A 1 (0.13%)
6968 A 1 (0.13%)
8639 A 1 (0.13%)
ST-11 11 NG 1 (0.13%)
W135 64 (8.28%)
Y 1 (0.13%)
5779 W135 1 (0.13%)
8637 W135 1 (0.13%)
ST-23 2953 Y 1 (0.13%)
4375 NG 2 (0.26%)
W135 1 (0.13%)
Y 8 (1.04%)
ST-167 767 Y 9 (1.17%)
2880 Y 1 (0.13%)
8620 Y 1 (0.13%)
ST-175 2881 W135 37 (4.79%)
8638 W135 1 (0.13%)
ST-181 181 X 46 (5.95%)
5789 X 2 (0.26%)
UAb 192 NG 2 (0.26%)
Y 1 (0.13%)
5403 X 15 (1.9%)
aNG, Non-groupable as determined by slide agglutination method.
bUA, Unassigned to any clonal complex.
doi:10.1371/journal.pone.0046019.t003
N. meningitidis in the Meningitis Belt, 2004–2010
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Figure 1. Serogroup distribution (%) in Burkina Faso, Mali and Niger in the period 2004–2010. In the figure, the few non-groupable
isolates were included together with those assigned to a serogroup on the basis of the capsule PCR and/or their molecular profile, except for ST-192
isolates (n = 2) that were likely to harbour a capsule null gene [36]. Black bars: serogroup A; white bars: serogroup W135; oblique strips: serogroup X;
vertical strips: serogroup Y.
doi:10.1371/journal.pone.0046019.g001
N. meningitidis in the Meningitis Belt, 2004–2010
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We here report the molecular characterization of 773 isolates
collected over this 7-year period. In our previous study,
encompassing a period of 15 years, data on a total of 357 isolates
had been collected [18]. This shows an overall improvement likely
resulting from a better use of the laboratory in meningitis diagnosis
in Africa and an increase networking of the WHO Collaborating
Centers. However, in comparison to the huge number of cases
occurring in the region, only a very small fraction of cases were
represented in our analysis. Relating to the data collated by the
WHO Inter country Support Team – West Africa the proportion
of culture-confirmed meningococcal cases included in our study
ranged from 4.2% in 2009 to 27.2% in 2007 (Table 4). The
representation of the different countries was variable; especially we
were unable to obtain strains from the Ivory Coast and Ethiopia.
From these two countries, however, only 32 and 51 cases,
respectively, have been culture-confirmed in this 7-year period
according to reported data [30]. From the remaining countries of
the meningitis belt that report to the WHO Inter country Support
Team – West Africa, our collection included from 2.5% of the
laboratory-confirmed cases from Niger (124 of 5061 cases) and up
to 70.6% of the laboratory-confirmed cases from Mali (132 of 187
cases). These data illustrate the great differences both in
surveillance systems and laboratory-based diagnosis of meningo-
coccal meningitis between countries of the belt.
Comparing our results for the 3 countries with most isolates
(Fig. 1) with the serogroup distribution reported in the WHO
Meningitis Weekly Bulletin, we see however similar proportions
and trends [30]. In Burkina Faso, 1,090 meningitis cases were
Figure 2. Evolution of the ST-5 complex in the meningitis belt in the period 1988–2010. The ST is shown within the bar, the country where
the new ST was first detected is indicated above and the locus changed to the left. The left end of the bar shows when the variant was first detected
and the right end shows the last reported isolation. The three dominant STs are marked with grey background.
doi:10.1371/journal.pone.0046019.g002
Table 4. Number (%) of studied isolates in relation to the number of laboratory-confirmed cases and number of reported cases
per year in countries of the meningitis belt.
Year No. of reported cases No. of CSF samples analysed No. of laboratory-confirmed MD cases
No. of isolates in the study
(%)
2004 31,712 NAa 809 71 (8.8)
2005 9,876 1,193 190 17 (8.9)
2006 41,526 6,215 1,572 225 (14.3)
2007 45,997 2,533 680 183 (26.9)
2008 33,381 3,413 1,134 107 (9.4)
2009 88,199 5,688 2,210 92 (4.2)
2010 30,103 4,132 1,238 78 (6.3)
Data source WHO Inter country Support Team – WestAfrica [30]. Numbers from the Democratic Republic of Congo have been removed to include only countries of the
meningitis belt.
aNA, Information not available.
doi:10.1371/journal.pone.0046019.t004
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laboratory-confirmed in-country for the 7-year period. The great
majority of isolates were serogroup A, except for 2004 and 2010
when a mixed situation was seen. In 2004, the second serogroup
was W135, while in 2010 serogroup X emerged toward the end of
the season; these situations were evidenced both by the in-country
surveillance and our strain collection.
Serogroup A dominated in Mali during the entire period. The
mixed population we described in 2006 and 2007 was not evident
from the WHO Meningitis Weekly Bulletin, where a few non-A
cases were laboratory-confirmed (1 of 36 in 2006 and 5 of 60 in
2007) [30].
In Niger the National Reference Laboratory (CERMES) in
Niamey provides a remarkable example of what kind of laboratory
support can be achieved in West Africa. More than one thousand
meningococcal meningitis cases have been confirmed and
serogrouped during the most severe epidemic years of 2006 and
2009. The representativeness of the small fraction of isolates from
Niger examined in this work is shown by the gradual increase in
serogroup X until 2006, followed by a new wave of serogroup A
cases in 2009.
For the other countries data are sporadic and our strain
collection can only show which clonal complex and specific variant
has been responsible for specific outbreaks.
Dominance of serogroup A
Serogroup A N. meningitidis was responsible for most of the
meningococcal outbreaks in 2004–2010, as it was for the period
1988–2003 [18]. The genetic diversity of serogroup A strains was
low as all 568 isolates belonged to only five closely related STs of
the ST-5 complex and all 344 isolates analyzed for PorA and FetA
were P1.20,9/F3-1. Interestingly, this porA-fetA sequence combi-
nation has been stable among the serogroup A strains that cause
disease in the meningitis belt for more than two decades, which
suggests that the immunologic selection pressure on these outer
membrane proteins is low. This is in contrast to the high variability
identified in the genes coding for these two potential vaccine
antigens among serogroup B isolates [31,32]. Serogroup A strains
of the ST-5 complex from other geographical areas may also
harbour the P1.20,9/F3-1 antigen combination, but variants,
especially for FetA, are not uncommon (http://pubmlst.org/
neisseria/). This observation should be considered when develop-
ing strategies for protein-based vaccines for Africa.
Indeed, SLVs and double locus variants were detected among
serogroup A isolates belonging to the ST-5 complex, and some of
them (ST-7 and ST-2859) were clearly successful in successive
clonal replacement within the complex. This study confirms
complete replacement of ST-5 with ST-7 that occurred after 2001
[18], as none of the strains from the period 2004–2010 were ST-5.
However, during this period ST-2859 which was first discovered
in Burkina Faso in 2003 completely replaced ST-7 in that country.
No serogroup A isolates recovered from Burkina Faso since 2003
were ST-7. The total replacement of ST-7 by ST-2859 in Burkina
Faso was also evidenced in a carriage study performed in 2009
when ST-2859 was identified as the only serogroup A clone
circulating among healthy carriers [28]. ST-2859 has spread from
Burkina Faso to Mali in 2004 and to Niger in 2008. In these two
countries, however, replacement of ST-7 by ST-2859 has not been
complete, as both clones were still recovered in Niger in 2009 and
in Mali in 2010. ST-2859 has not been observed in the other
countries of the meningitis belt. The severe epidemic in Nigeria in
2009 (more than 56,000 reported cases) was caused by ST-7.
Continuous spread of serogroup W135
The first large epidemic caused by serogroup W135, ST-11,
occurred in Burkina Faso in 2002, probably following amplifica-
tion of this clone after the annual Hajj pilgrimages of 2000 and
2001 [7,33]. Prior to the Burkina Faso epidemic, serogroup W135
ST-11 isolates had been identified in Chad in 1996, Cameroon
and Senegal in 2000, CAR in 2001, showing a large dispersion of
the clone in the meningitis belt [18]. In the period 2004–2010, the
ST-11 complex was identified in all the countries of the meningitis
belt where isolates were obtained, except for Niger and Togo.
While ST-11 complex was present in Niger in 2002 and 2003,
from 2004 the W135 isolates recovered from that country
belonged to ST-2881 of the ST-175 complex. In 2010, W135
predominated in Niger [30], but no isolates were available to us.
Laboratory identification of the etiological agent was mainly
performed by PCR, but all 9 W135 isolates tested by Collard and
co-workers [4] belonged to ST-11. The ST-11 complex seemed to
disappear also from Burkina Faso after 2006 and the few W135
recovered then belonged to the ST-175 complex. In Chad
serogroup W135 dominated during most of the period 2004–
2010, belonging either to ST-11 (2005, 2006, 2008–2010) or ST-
2881 (2004 and 2007). In the years 2008–2010, the proportion of
serogroup W135 in Chad decreased while the proportion of
serogroup A increased (Fig. 1). In Niger, isolates of serogroup
W135 belonging to ST-11 accounted for nearly 50% of the case
isolates in 2010 [4]. In contrast to the ST-11 complex, the ST-175
complex has not been associated with major epidemics and is
responsible for endemic disease cases. This clonal complex is
geographically widespread and has been identified in meningo-
coccal carriage studies in Europe and Asia (http://pubmlst.org/
neisseria/).
Emergence of serogroup X
Carriage and sporadic disease-associated serogroup X isolates
have been detected in the meningitis belt as early as in the 1990s
[6,8,34]. During the 7-year period analysed here, Niger experi-
enced a serogroup X outbreak in 2006 [3] and the responsible
epidemic strain was ST-181 (Table 1). Serogroup X, however,
declined later on in Niger and represented less than 1% of the
isolates in 2010 [4]. Delrieu and coworkers reported a serogroup
X outbreak in one district in Togo in 2007 [35]. Although no
isolates had been stored, MLST on cerebrospinal samples revealed
ST-181 [35]. This serogroup X strain was present in Burkina Faso
in a small fraction (4%) of the cases in 2007, but emerged as an
important cause of disease in 2010 where it was identified in 7 of
our 10 meningococcal isolates. Serogroup X outbreaks occurring
in northern and central regions of Burkina Faso in 2010 have been
documented [35]. In 2009, serogroup X ST-181 had been
identified in 0.44% of healthy carriers in Burkina Faso [28], with a
higher prevalence in the north-east district of Kaya, close to Niger
(1.05%). The circulation of serogroup X meningococci among
asymptomatic carriers and the high incidence of serogroup X
disease before MenAfriVac introduction should be kept in mind
when evaluating possible serogroup replacement following use of
the vaccine. The possible spread of serogroup X has to be closely
monitored in the coming years as there are yet no available
vaccines against this serogroup.
Interestingly, serogroup X meningococcal disease also emerged
in Kenya and in Uganda in 2006, but these cases were caused by a
strain unrelated to the ST-181 complex [8].
Conclusions
Our data show that before introduction of MenAfriVac in the
African meningitis belt, serogroup A N. meningitidis of the ST-5
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complex remains the predominant disease-causing clonal complex,
with two STs (ST-7 and ST-2859) contributing to severe outbreaks
in different countries. The situation, however, is heterogeneous
both temporally and geographically. After the emergence of
serogroup X ST-181 complex in Niger in 2006, the clone became
a significant cause of disease in Burkina Faso in 2010 before
vaccine introduction. Improved laboratory confirmation of men-
ingitis cases is essential to assess changes in the disease
epidemiology. Culture of the disease-causing organism and their
genotyping are necessary to a better understanding of the bacterial
population dynamics.
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